pipette
ENEnglish

Glioblastoma model mouse rescue from mortality by brain-targeted catalytically-enhanced angiotensin-converting enzyme 2 mutant-antibody fusion protein

P. Heinzelman, G. R. Nageeb, J. Choi, J. Liu, S. Y. Lee, P. A. Romero, M. Lim

PreprintAfirmaciones fuertes, leer con cuidado

En palabras de los autores

We have discovered that an engineered angiotensin-converting enzyme 2 (ACE2)-brain-targeted antibody fusion protein, referred to as ACE2dm-s1, improves survival of CT-2A xenograft glioblastoma (GBM) model mice when administered in combination with a small molecule STING agonist cancer therapeutic. Particularly striking about these survival results is that prior efforts that used losartan, a small molecule angiotensin receptor antagonist that acts on the same Renin-Angiotensin System (RAS) axis that is affected by the action of ACE2dm-s1, showed that this small molecule provided no survival benefit when used as an element of combination therapy in the same CT-2A GBM model used in our experiments. The improved CT-2A mouse survival, which was not observed for ACE2dm-s1 or STING agonist monotherapy, combines with our flow cytometry study results that revealed an ACE2dm-s1-mediated shift of brain immune cell populations toward an anti-tumoral composition to establish ACE2dm-s1's utility as a tumor microenvironment (TME) modulator that could serve as an adjuvant in increasing the efficacy of wide range of cancer treatment modalities including chemotherapeutic agents, immune checkpoint inhibitors, and CAR-T cells.

Resultado principalEl resumen no menciona limitaciones.

Apareció: jueves, 5 de noviembre. bioRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.11.03.763994